Abstract
Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit-risk profile. https://bit.ly/3SbisW3.
| Original language | English |
|---|---|
| Article number | 00695-2022 |
| Number of pages | 4 |
| Journal | ERJ Open Research |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 May 2023 |
Fingerprint
Dive into the research topics of 'Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver